Hugues Bultot

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York.

Global Health Investment Fund seeks investment opportunities in global health technologies. The fund invests in new drugs & vaccines, emerging diagnostic tools, child-friendly formulations of existing products, expanding manufacturing capacity and other applications. It provides financing in the form of mezzanine for later-stage capital requirements.

Catalent MSTC, Inc. provides full service contract development and manufacturing services (CDMO) for cell therapy companies. It offers process and assay development, quality management, and cGMP cell therapy manufacturing services. The company was incorporated on December 27, 2017 and is headquartered in Dover, DE.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Orgenesis Biotech Israel Ltd. provides process development capabilities, custom engineering, platform design and optimization and cells and viruses cyclic guanosine monophosphate manufacturing services. The firm also offers assay devlopment and validation services. The company was founded by Ohad Karnieli and is headquartered in Nesher, Israel.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Noshaq SA is an independent private equity/venture capital firm founded in 1985. Noshaq SA is headquartered in Liege.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Adiposs SA is a Swiss medical imaging company that has developed imagebat-enhanced CT scan technology. The company is based in Plan-les-Ouates, Switzerland. The technology is fast, pain-free, and can be made available in every hospital and organization worldwide that provides CT scans. The company's co-inventor, Andrej Babic, has co-authored more than 30 scientific papers and holds several patents in the fields of medical imaging, photodynamic therapy, and nanotechnology. The company's team includes experts in preclinical development, clinical trials, and drug development across multiple therapeutic areas. Adiposs was founded by Nathalie Stransky-Heilkron, Andrej Babic, and Justyna Plewka Ma. Andrej Babic has been the CEO since incorporation.

Kupando GmbH is a German biopharmaceutical company that develops agonists to stimulate innate immunity. The company is based in Schoenefeld, Germany. The company was founded in 2018 by Johanna Holldack, who has been the CEO since 2018.

Cube Labs Srl (Cube Labs) is a venture capital subsidiary of Cube Labs SpA founded in 2013 by Filippo Surace and Renato del Grosso. The firm is headquartered in Rome, Italy.

Limula Biotech operates as an automated gene therapy manufacturing platform.

AJ Biologics Sdn. Bhd develops and manufactures biological products. It specializes in vaccine formulations. The company is headquartered in Kuala Lumpur, Malaysia.

Founded in 1900, Schering-Plough SAS is a French pharmaceutical company that manufactures pharmaceutical products. Part of Merck & Co., Inc., the company is based in Puteaux, France.

Health Technology Holding Srl (HTC), is a venture capital subsidiary of Gefim SpA founded in 2019. The firm is headquartered in Milan, Italy.

FIDE Capital SA is an independent wealth management firm headquartered in Brussels, Belgium. The firm was founded in 1996 as Compagnie de Gestion Privée and became FIDE Capital SA in 2012. It offers discretionary asset management services or investment advice.

TheClubDeal Capital Advisors SA (Private Equity) is a private equity/venture capital division of TheClubDeal Capital Advisors SA founded in 2016 by Nicolas de Moreau and Jean-Marc Legrand. The firm headquartered in Brussels, Belgium.

YUST Group NV provides real estate services. The company is based in Antwerp, Belgium and has subsidiaries in Belgium. The Belgian company was founded in 2018. Stephane Verbeeck has been the CEO of the company since 2019.

BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France.

Quantoom Biosciences SA is a Belgian company that is focused on revolutionizing mRNA production through the development of their platform, ntensify. The private company is based in Nivelles, Belgium. This platform includes DNA amplification and RNA manufacturing, with the ntensify systems being the core of their RNA production technology. The company is made up of a team of scientists, engineers, and clinicians who are dedicated to addressing the major challenges in DNA and RNA production for vaccines and therapeutics.

Insight Biopharmaceuticals Ltd. is an Israeli company that manufactures and commercializes biosimilars and new antibody therapeutics. The private company is based in Rehovot, Israel.

Metalmark Capital LLC (Metalmark Capital) is a private equity firm founded by John J. Moon in 1986. The firm is headquartered in New York.

Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.

Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom.

Frontier Nutrition, Inc. develops and manufactures fortified packaged food. Its recipes are localized for traditional diets, taste, and nutrition. The company was founded by Eddie Bearnot and Tanveer Ali on August 18, 2016 and is headquartered in DE.

LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023.